C, Hansen B, Denaro M: Glucose-lowering and in-sulin-sensitizing actions of exendin-4: Studies inobese diabetic ( ob/ob , db/db ) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys ( Macaca mulatta ). Diabetes 1999;48:1026–1034. 11. Parkes DG, Pittner R, Jodka C, Smith P, Young A: In- sulinotropic actions of exendin-4 and glucagon-likepeptide-1 in vivo and in vitro. Metabolism 2001;50:583–589. 12. Egan JM, Clocquet AR, Elahi D: The insulinotropic ef- fect of acute exendin-4 administered to humans: Com-parison of nondiabetic state to type 2 diabetes. J ClinEndocrinol Metab 2002;87:1282–1290. 13. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O: Ef-fect of intravenous infusion of exenatide (synthetic ex-endin-4) on glucose-dependent insulin secretion andcounterregulation during hypoglycemia. Diabetes2004;53:2397–2403. 14. Gedulin BR, Jodka C, Hoyt J: Exendin-4 (AC2993) de-